Drug intelligence / Profile preview

JRF102

Development stage: Unknown
Lead developer: Shenzhen Jinruijiye Biotechnology
Modality: Small Molecules

Overview

JRF102 is a small molecule inhibitor of MAPK-activated protein kinase 2 (MK2) being developed by Shenzhen Jinruijiye Biotechnology for the treatment of solid tumors. MK2 is a serine/threonine kinase that acts as a downstream effector of the p38 mitogen-activated protein kinase (MAPK) pathway, playing a critical role in the regulation of inflammatory cytokines and the cellular response to DNA damage. By inhibiting MK2, JRF102 aims to suppress tumor growth and modulate the inflammatory environment within the tumor microenvironment. The drug is currently in early-stage clinical development, with its status indicated as Preclinical/Phase 1 in the company's 2024-2026 development roadmap.

Targets

MK2 (Mitogen-activated protein kinase-activated protein kinase 2)

Beyond the preview

Go deeper on JRF102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JRF102.

Explore the full profile